Skip to main content
SpringerLink
Log in

Systemic Chemotherapy

  • Chapter
  • First Online:
Oral Cancer

  • 3379 Accesses

Abstract

Systemic chemotherapy for oral squamous cell carcinoma is generally employed in the following situations: (a) postoperative adjuvant concurrent chemoradiotherapy for patients with high-risk features, (b) postoperative adjuvant chemotherapy, (c) preoperative concurrent chemoradiotherapy followed by surgery for advanced resectable patients, (d) concurrent chemoradiotherapy as primary treatment for cases unable to tolerate or unsuited for surgery or as salvage treatment in the persistent or recurrent disease setting, (e) neoadjuvant chemotherapy, and (f) palliative chemotherapy. The recent addition of cetuximab to radiotherapy or platinum-based chemotherapy has produced a significant improvement in overall survival for head and neck cancer. Further, numerous novel molecular targeting drugs are now under investigation for head and neck cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bessell A, Glenny AM, Furness S, Clarkson JE, Oliver R, Conway DI, Macluskey M, Pavitt S, Sloan P, Worthington HV (2011) Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev (9):CD006205. 10.1002/14651858.CD006205.pub3

  2. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N (1996) Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 36(5):999–1004

    Article  CAS  PubMed  Google Scholar 

  3. Smid L, Budihna M, Zakotonik B (2003) Postoperative concomitant irradiation and chemotherapy with mitomycin and bleomycin for advanced head and neck carcinoma. Int J Radiat Oncol Biol Phys 56:1055–1062

    Article  CAS  PubMed  Google Scholar 

  4. Al-Sarraf M, Thomas F, Roger W (1997) Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced respectable head and neck cancers: RTOG 88–24. Int J Radiat Oncol Biol Phys 37:777–782

    Article  CAS  PubMed  Google Scholar 

  5. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952. doi:10.1056/NEJMoa032641

    Article  CAS  PubMed  Google Scholar 

  6. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944. doi:10.1056/NEJMoa032646

    Article  PubMed  Google Scholar 

  7. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843–850. doi:10.1002/hed.20279

    Article  PubMed  Google Scholar 

  8. Fietkau R, Lautenschlager C, Sauer R, Dunst J, Becker A, Baumann M (2006) Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: result of the German phase III trial ARO 96–3. Proc Am Soc Clin Oncol 24:5507 (abstr 5507)

    Google Scholar 

  9. Argiris A, Karamouzis MV, Johnson JT, Heron DE, Myers E, Eibling D, Cano E, Urba S, Gluckman J, Grandis JR, Wang Y, Agarwala SS (2008) Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer. Laryngoscope 118:444–449

    Article  CAS  PubMed  Google Scholar 

  10. Winquist E, Oliver T, Gilbert R (2007) Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck 29(1):38–46. doi:10.1002/hed.20465

    Article  PubMed  Google Scholar 

  11. Tsukuda M, Ogasawara H, Kaneko S, Komiyama S, Horiuchi M, Inuyama Y (1994) A prospective randomized trial of adjuvant chemotherapy with UFT for head and neck carcinoma. Head and neck UFT study group. Gan To Kagaku Ryoho (Cancer Chemother) 21(8):1169–1177

    CAS  Google Scholar 

  12. Taguchi T, Kubota A, Yoshino K, Tomita K, Kohno N, Kawabata K, Fukushima M, Tsukahara K, Takemura H, Hasegawa Y, Terada T, Nagahara K, Nakatani H, Higaki Y, Iwae S, Beppu T, Hanamure Y, Teramukai S, Fujii M (2013) Adjuvant chemotherapy with S-1 after curative treatment in patients with head and neck cancer (ACTS-HNC). J Clin Oncol 31:suppl(abstr 6004)

    Google Scholar 

  13. Lung T, Tăşcău OC, Almăşan HA, Mureşan O (2007) Head and neck cancer, treatment, evolution and post therapeutic survival part 2: a decade's results 1993–2002. J Craniomaxillofac Surg 35:126–131

    Article  PubMed  Google Scholar 

  14. Freier K, Engel M, Lindel K, Flechtenmacher C, Mühling J, Hassfeld S, Hofele C (2008) Neoadjuvant concurrent radiochemotherapy followed by surgery in advanced oral squamous cell carcinoma (OSCC): a retrospective analysis of 207 patients. Oral Oncol 44:116–123

    Article  CAS  PubMed  Google Scholar 

  15. Kirita T, Ohgi K, Shimooka H, Yamanaka Y, Tatebayashi S, Yamamoto K, Mishima K, Sugimura M (1999) Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results. Oral Oncol 35:597–606

    Article  CAS  PubMed  Google Scholar 

  16. Kirita T, Shimooka H, Yamanaka Y, Tatebayashi S, Yamamoto K, Nishimine M, Sugimura M (2001) Prognostic value of response to preoperative chemoradiotherapy and residual tumor grades in tongue carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91:293–300

    Article  CAS  PubMed  Google Scholar 

  17. Klug C, Berzaczy D, Voracek M, Millesi W (2008) Preoperative chemoradiotherapy in the management of oral cancer: a review. J Craniomaxillofac Surg 36:75–88. doi:10.1016/j.jcms.2007.06.007

    Article  PubMed  Google Scholar 

  18. Mohr C, Bohndorf W, Carstens J, Härle F, Hausamen JE, Hirche H, Kimmig H, Kutzner J, Mühling J, Reuther J et al (1994) Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone. A prospective, multicentric, randomized DOSAK study of advanced squamous cell carcinoma of the oral cavity and the oropharynx (a 3-year follow-up). Int J Oral Maxillofac Surg 23:140–148

    Article  CAS  PubMed  Google Scholar 

  19. Kirita T, Yamanaka Y, Imai Y, Yamakawa N, Aoki K, Nakagawa Y, Yagyuu T, Hasegawa M (2012) Preoperative concurrent chemoradiotherapy for stages II-IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy. Int J Oral Maxillofac Surg 41:421–428. doi:10.1016/j.ijom.2011.12.003

    Article  CAS  PubMed  Google Scholar 

  20. Kessler P, Grabenbauer G, Leher A, Schultze-Mosgau S, Rupprecht S, Neukam FW (2004) Patients with oral squamous cell carcinoma. Long-term survival and evaluation of quality of life-initial results obtained with two treatment protocols in a prospective study. Mund Kiefer Gesichtschir 8:302–310

    Article  CAS  PubMed  Google Scholar 

  21. Colella G, Cannavale R, Pentenero M, Gandolfo S (2007) Oral implants in radiated patients: a systematic review. Int J Oral Maxillofac Implants 22:616–622

    PubMed  Google Scholar 

  22. Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K (2009) Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck 31(8):1013–1021. doi:10.1002/hed.21062

    Article  PubMed  Google Scholar 

  23. Pignon JP, le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14. doi:10.1016/j.radonc.2009.04.014

    Article  PubMed  Google Scholar 

  24. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14):2787–2799. doi:10.1200/JCO.2003.01.504

    Article  CAS  PubMed  Google Scholar 

  25. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19(3):183–232

    Article  CAS  PubMed  Google Scholar 

  26. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ (1996) Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78(6):1284–1292. doi:10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X

    Article  CAS  PubMed  Google Scholar 

  27. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350–7356

    CAS  PubMed  Google Scholar 

  28. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15

    Article  CAS  PubMed  Google Scholar 

  29. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90(11):824–832

    Article  CAS  PubMed  Google Scholar 

  30. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1(11):1311–1318

    CAS  PubMed  Google Scholar 

  31. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59(8):1935–1940

    CAS  PubMed  Google Scholar 

  32. Harari PM, Huang SM (2001) Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49(2):427–433

    Article  CAS  PubMed  Google Scholar 

  33. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6(2):701–708

    CAS  PubMed  Google Scholar 

  34. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578, 354/6/567 [pii] 10.1056/NEJMoa053422

    Article  CAS  PubMed  Google Scholar 

  35. Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, Cantu G (2003) Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 21(2):327–333

    Article  CAS  PubMed  Google Scholar 

  36. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704

    Article  CAS  PubMed  Google Scholar 

  37. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715

    Article  CAS  PubMed  Google Scholar 

  38. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12(2):153–159. doi:10.1016/S1470-2045(10)70279-5

    Article  CAS  PubMed  Google Scholar 

  39. Cohen E, Karrison T, Kocherginsky M (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30(Suppl 15):356s (abstr 5500)

    Google Scholar 

  40. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264. doi:10.1016/S1470-2045(13)70011-1

    Article  CAS  PubMed  Google Scholar 

  41. Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY (2013) Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 31(6):744–751. doi:10.1200/JCO.2012.43.8820

    Article  CAS  PubMed  Google Scholar 

  42. Veronesi A, Zagonel V, Tirelli U, Galligioni E, Tumolo S, Barzan L, Lorenzini M, Comoretto R, Grigoletto E (1985) High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol 3(8):1105–1108

    CAS  PubMed  Google Scholar 

  43. Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, Veevers A, Stell PM (1985) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 15(3):283–289

    Article  CAS  PubMed  Google Scholar 

  44. Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D (1986) Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 4(10):1506–1509

    CAS  PubMed  Google Scholar 

  45. de Andres BL, Lopez Pousa A, Alba E, Sampedro F (1986) Carboplatin, an active drug in advanced head and neck cancer. Cancer Treat Rep 70(10):1173–1176

    Google Scholar 

  46. Al-Sarraf M, Metch B, Kish J, Ensley J, Rinehart JJ, Schuller DE, Coltman CA Jr (1987) Platinum analogs in recurrent and advanced head and neck cancer: a Southwest oncology group and Wayne state university study. Cancer Treat Rep 71(7–8):723–726

    CAS  PubMed  Google Scholar 

  47. Inuyama Y, Togawa K, Morita M, Takeoda S, Kaneko T, Takemiya S, Ono I, Nomura Y, Okuda M, Kikuchi K et al (1988) Phase II study of carboplatin in head and neck cancer. Gan To Kagaku Ryoho (Cancer Chemother) 15(7):2131–2138

    CAS  Google Scholar 

  48. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest oncology group study. J Clin Oncol 10(8):1245–1251

    CAS  PubMed  Google Scholar 

  49. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC early clinical trials group. Ann Oncol 5(6):533–537

    CAS  PubMed  Google Scholar 

  50. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14(5):1672–1678

    CAS  PubMed  Google Scholar 

  51. Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, Groult V, Bordessoule S, Janot F, De Forni M, Armand JP (1999) A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 81(3):457–462. doi:10.1038/sj.bjc.6690715

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Inuyama Y, Kataura A, Togawa K, Saijo S, Satake B, Takeoda S, Konno A, Ebihara S, Sasaki Y, Kida A, Kanzaki J, Ichikawa G, Kono N, Moriyama H, Kamata S, Miyake H, Sakai M, Horiuchi M, Kubota A, Tsukuda M, Matsuura H, Baba S, Saito H, Matsunaga T, Taguchi T et al (1999) Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Gan To Kagaku Ryoho (Cancer Chemother) 26(1):107–116

    CAS  Google Scholar 

  53. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, Madroszyk A, Ronchin P, Schneider M, Bleuze JP, Blay JY, Pivot X (2004) Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 40(14):2071–2076. doi:10.1016/j.ejca.2004.05.019

    Article  CAS  PubMed  Google Scholar 

  54. Smith RE, Thornton DE, Allen J (1995) A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 22(3 Suppl 6):41–46

    CAS  PubMed  Google Scholar 

  55. Forastiere AA, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern cooperative oncology group trial (PA390). Cancer 82(11):2270–2274, 10.1002/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q [pii]

    Article  CAS  PubMed  Google Scholar 

  56. Brotherton T Multicenter phase II trial of paclitaxel (taxol) (T): Weekly one-hour infusion in previously treated advanced head/neck cancer (AHNC). In: ASCO 2001, 2001. p abstract 921

    Google Scholar 

  57. Tahara M, Minami H, Hasegawa Y, Tomita K, Watanabe A, Nibu K, Fujii M, Onozawa Y, Kurono Y, Sagae D, Seriu T, Tsukuda M (2011) Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer. Cancer Chemother Pharmacol 68(3):769–776. doi:10.1007/s00280-010-1550-3

    Article  CAS  PubMed  Google Scholar 

  58. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10(2):257–263

    CAS  PubMed  Google Scholar 

  59. Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53(19):4637–4642

    CAS  PubMed  Google Scholar 

  60. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18(4):904–914

    CAS  PubMed  Google Scholar 

  61. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8(5):994–1003

    CAS  PubMed  Google Scholar 

  62. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345. doi:10.1056/NEJMoa033025

    Article  CAS  PubMed  Google Scholar 

  63. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK (2001) Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7(5):1204–1213

    CAS  PubMed  Google Scholar 

  64. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5568–5577. doi:10.1200/JCO.2005.07.119

    Article  CAS  PubMed  Google Scholar 

  65. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5578–5587. doi:10.1200/JCO.2005.07.120

    Article  CAS  PubMed  Google Scholar 

  66. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16):2171–2177. doi:10.1200/JCO.2006.06.7447

    Article  CAS  PubMed  Google Scholar 

  67. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern cooperative oncology group study. J Clin Oncol 23(34):8646–8654. doi:10.1200/JCO.2005.02.4646

    Article  PubMed  Google Scholar 

  68. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127. doi:10.1056/NEJMoa0802656

    Article  CAS  PubMed  Google Scholar 

  69. Mesia R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D, Gross A, Vermorken JB (2010) Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 21(10):1967–1973. doi:10.1093/annonc/mdq077

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Peeters M, Cohn A, Kohne CH, Douillard JY (2012) Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Clin Colorectal Cancer 11(1):14–23. doi:10.1016/j.clcc.2011.06.010

    Article  CAS  PubMed  Google Scholar 

  71. Vermorken JB, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14(8):697–710. doi:10.1016/S1470-2045(13)70181-5

    Article  CAS  PubMed  Google Scholar 

  72. Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, Sorensen P, Nielsen T, Lisby S, Clement PM (2011) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12(4):333–343. doi:10.1016/S1470-2045(11)70034-1

    Article  CAS  PubMed  Google Scholar 

  73. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE (2009) Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27(11):1864–1871. doi:10.1200/JCO.2008.17.0530

    Article  CAS  PubMed  Google Scholar 

  74. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22(1):77–85. doi:10.1200/JCO.2004.06.075

    Article  CAS  PubMed  Google Scholar 

  75. Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA (2013) Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 31(11):1405–1414. doi:10.1200/JCO.2012.45.4272

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE (2012) A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 18(8):2336–2343. doi:10.1158/1078-0432.CCR-11-2825

    Article  PubMed  Google Scholar 

  77. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350. doi:10.1124/jpet.112.197756

    Article  CAS  PubMed  Google Scholar 

  78. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711. doi:10.1038/onc.2008.109

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Sequist L, Yang J-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater S, Orlov S, Tsai C-M, Boyer M, Su W-C, Bennouna J, Kato T, Gorbunova V, Lee K, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Afatinib or cisplatin/pemetrexed in pulmonary adenocarcinoma patients with epidermal growth factor receptor mutations. J Clin Oncol 20;31(27):3327–3334

    Google Scholar 

  80. Schutze C, Dorfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M (2007) Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 183(5):256–264. doi:10.1007/s00066-007-1696-z

    Article  PubMed  Google Scholar 

  81. Solca F, Baum A, Krause M, Baumann M, Wong K, Greulich H, Guenther A (2007) Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2, in models of head and neck cancer. Eur J Cancer Suppl 5(4):326–327

    Article  Google Scholar 

  82. Cupissol D, Seiwert T, Fayette J, Ehrnrooth E, Blackman A, Cong X, Cohen E (2013) A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of stage 2 (S2) following crossover. J Clin Oncol 31(Suppl 15):363s (abstr 6001)

    Google Scholar 

  83. Psyrri A, Seiwert TY, Jimeno A (2013) Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book 33:246–255. doi:10.1200/EdBook_AM.2013.33.246

    Article  Google Scholar 

  84. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern cooperative oncology group. J Clin Oncol 23(15):3562–3567. doi:10.1200/JCO.2005.01.057

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

    Makoto Tahara M.D., Ph.D.

  2. Department of Oral and Maxillofacial Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan

    Tadaaki Kirita D.D.S., D.MSc.

Authors
  1. Makoto Tahara M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tadaaki Kirita D.D.S., D.MSc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadaaki Kirita D.D.S., D.MSc. .

Editor information

Editors and Affiliations

  1. Dept of Oral and Maxillofacial Surg, Nara Medical University, Kashihara, Nara, Japan

    Tadaaki Kirita

  2. Oral Cancer Center, Tokyo General Hospital, Tokyo, Tokyo, Japan

    Ken Omura

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Japan

About this chapter

Cite this chapter

Tahara, M., Kirita, T. (2015). Systemic Chemotherapy. In: Kirita, T., Omura, K. (eds) Oral Cancer. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54938-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-54938-3_12

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-54937-6

  • Online ISBN: 978-4-431-54938-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation